Claims for Patent: 11,123,343

Summary for Patent: 11,123,343

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/063,364
Patent Claims:	1. A method of treating treatment resistant depression, comprising administering: bupropion, at a daily dose that is about 150 mg to about 250 mg, and dextromethorphan, at a daily dose that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are administered in a dosage form containing both the bupropion and the dextromethorphan as the only therapeutically active compounds; wherein the bupropion is bupropion hydrochloride, or the free base or another salt form of bupropion and the dextromethorphan is dextromethorphan hydrobromide, or the free base or another salt form of dextromethorphan; wherein the daily doses of the bupropion and the dextromethorphan are orally administered once a day or are a total of twice daily doses; and wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion; and wherein a therapeutic effect upon the human being is observed. 2. The method of claim 1, wherein the human being experiences an improvement in a depressive symptom as compared to baseline. 3. The method of claim 1, wherein orally administering the dosage form is more effective in treating treatment resistant depression than a placebo. 4. The method of claim 1, wherein orally administering the dosage form is more effective in treating treatment resistant depression than orally administering the same amount of the dextromethorphan alone. 5. The method of claim 1, wherein the dosage form is orally administered once daily. 6. The method of claim 1, wherein the dosage form is orally administered twice daily. 7. The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days. 8. The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days. 9. The method of claim 1, wherein the weight ratio of the dextromethorphan to the bupropion in the dosage form is about 0.3 to about 0.5. 10. The method of claim 1, wherein the dosage form is solid. 11. The method of claim 1, wherein the dosage form is orally administered once a day for 1 day, and is administered twice a day thereafter. 12. The method of claim 1, wherein the dosage form is orally administered once a day for 2 days, and is administered twice a day thereafter. 13. The method of claim 1, wherein the dosage form is orally administered once a day for 3 days, and is administered twice a day thereafter. 14. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing anxiety. 15. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in improving concentration, reducing mental slowing, or a combination thereof. 16. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in improving mood, reducing feelings of intense sadness, reducing despair, reducing pessimistic worry, or a combination thereof. 17. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing agitation, irritability, restlessness, or a combination thereof. 18. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing guilt, feelings of worthlessness, self-deprecation, or a combination thereof. 19. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing insomnia. 20. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing anorexia, appetite loss, weight loss, or a combination thereof. 21. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing weight gain. 22. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing decreased energy, fatigue, decreased libido, or a combination thereof. 23. The method of claim 1, wherein orally administering the dosage form is more effective than a placebo in reducing abnormal hormonal circadian rhythms.